Lilly's TRIUMPH clinical program includes multiple Phase III trials evaluating retatrutide across different patient populations and endpoints: Seven additional Phase III readouts are expected throughout 2026, covering populations with type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and other obesity-related comorbidities Cardiovascular outcomes data the gold standard for demonstrating that weight loss translates into reduced heart attacks, strokes, and cardiovascular death will be critical for retatrutide's regulatory and commercial positioning Head-to-head trials comparing retatrutide directly to existing therapies may provide definitive comparative efficacy data The Drug vs
AI-Driven insights into TGF- regulation Artificial intelligence (AI) tools like AlphaFold have uncovered unexpected molecular interactions, such as the extensive interface between fibrillin and latent TGF- binding protein 1 (LTBP1) in supporting TGF- activation (Lockhart-Cairns et al
These devices need precision engineering, reliable materials and strict quality control systems
Although a specific skin problem may not be cured right away, other positive changes will likely occur sooner
Interested to learn more about B12 deficiency
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study